The JAK2/STAT3 pathway is involved in the anti‐melanoma effects of atractylenolide I.

Abstract: In this study, we aimed to investigate the anti‐melanoma effects and the JAK2/STAT3 pathway‐related mechanism of action of atractylenolide I in human melanoma cells. Our results showed that atractylenolide I effectively reduced viability, induced apoptosis and inhibited migration of melanoma cells. Meanwhile, atractylenolide I decreased the protein expression levels of phospho‐JAK2 and phospho‐STAT3, and in turn downregulated the mRNA levels of STAT3‐targeted genes, including Bcl‐xL, MMP‐2 and MMP‐9. Furthermore, the cytotoxic effect of atractylenolide I was attenuated in STAT3‐overactivated A375 cells. These findings indicate that inhibition of JAK2/STAT3 signalling contributes to the anti‐melanoma effects of atractylenolide I. [ABSTRACT FROM AUTHOR]